Answers are grounded in this paper and cite their sources.
Objective To determine early predictive markers and to develop prognostic models for self-reported persistence of Long COVID syndrome at 36 months after hospitalisation. Design A prospective observational study with cross-sectional analyses at predefined follow-up points. Setting A tertiary care hospital. Participants 221 patients hospitalised for COVID-19 underwent detailed clinical, functional, imaging and survey-based symptom assessment prior to discharge and at 1 month, followed by a 3-year longitudinal follow-up on symptoms. 159 patients (mean age 53.1±13.6 years, 55% female) completed the 36-month assessment and were included in the final analysis. Main outcome measure Self-reported persistence of Long COVID symptoms at 36 months after hospital discharge. Results At 36 months after discharge, 66 (41%) patients reported persistent Long COVID symptoms. This group did not differ in age or sex structure, more frequently reported ongoing symptoms at 3 months (91% vs 59%, p<0.001) and 12 months (77% vs 13%, p<0.001), had longer time to hospitalisation (10.2±3.4 vs 5.2±3.9 days, p<0.001) and higher Charlson comorbidity index (0.61±0.96 vs 0.33±0.56, p=0.022), higher in-hospital creatinine (109 (100–119) vs 96 (85–105) µmol/L, p<0.001), aspartate aminotransferase (AST) (43 (37–55) vs 32 (21–47) IU/L, p=0.003), and alanine aminotransferase (47 (30–128) vs 42 (26–62) IU/L, p=0.011) and paradoxically lower Galectin-3 (8.6±0.7 vs 9.0±0.5 ng/mL, p<0.001) and sST2 (23.2±13.7 vs 29.7±15.8 ng/mL, p=0.012). No significant differences were found in inflammatory markers, minimal in-hospital peripheral capillary oxygen saturation, need for oxygen supplementation, pulmonary involvement on CT or lung ultrasound, and clinically negligible differences detected in cardiovascular evaluation, with a baseline tendency to minimal hypercontractility and lower flow-mediated dilation (10.1±5.1 vs 12.9%±5.9%, p=0.006) and marginally worse early dynamics of diastolic indices in Long COVID group. In 6-Minute Walking Test, no differences were observed at baseline but patients with Long COVID reported higher postexertional fatigue (3.3±2.1 vs 1.9±1.6, p<0.001) and dyspnoea (3.4±1.7 vs 2.5±1.8, p=0.027) despite lower blood oxygen desaturation (1.7±1.7 vs 2.8%±2.4%, p=0.014) at 1 month. In symptom assessment, longitudinal trajectories differed significantly for Medical Research Council Dyspnoea (p=0.004), post-COVID functional scale (p<0.001), EFTER-COVID study physical symptoms (p<0.001) and Symptom Burden Questionnaire for Long COVID Memory, Thinking and Communication (p<0.001) scores, reaching maximal differences by 3–12 months, while respiratory scores showed no sustained differences. A simple artificial neural network model combining predischarge variables (sex, age, creatinine, AST, weight loss, duration of hospitalisation and 6-Minute Walk Distance) with 3-month multidimensional symptom assessment achieved a 92% accuracy (area under the receiver operating characteristic, AUROC 0.902), consistently outperforming other machine learning classifiers. A simplified model using only 3-month survey data, age, sex and hospitalisation duration retained high discrimination accuracy (88%, AUROC 0.850). Conclusions 41% of hospitalised COVID-19 patients reported persistent symptoms at 36 months, preceded by early divergence in patient-reported symptoms despite comparable recovery of objective functional parameters. Predictive models incorporating 3-month multidimensional symptom assessment and routine clinical variables accurately identified patients at risk, outperforming later reassessment strategies and supporting early risk stratification.
No takes yet. Share an insight, caveat, or question.
Honchar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: